Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rasesh Shah

Vascular Surgery Chesapeake, VA Medical Doctor

NPI 1639140056 CMS profile 209616

725 Volvo Pkwy Ste 210B, Chesapeake, VA 23320

Open in the dashboard

General payments

$465,440

694 records reported · program years 2019–2025

Research payments

$14

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$109,149 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Rasesh Shah of Chesapeake, VA is reported in the CMS Open Payments database as having received $465,440 across 694 general payments and $14 in research payments paid to them. Separately, studies naming them as principal investigator received $109,149 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,723 23
2024 General $36,638 76
2023 General $75,973 106
2022 General $102,735 145
2021 General $86,932 127
2020 General $73,492 66
2019 General $75,947 151
2019 Research $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rasesh Shah
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Rasesh Shah were reported at $13,723. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Rasesh Shah Vascular Surgery median Middle half National median
2019 $75,947 $796 $226–$2,363 $163
2020 $73,492 $348 $118–$1,110 $114
2021 $86,932 $471 $158–$1,421 $132
2022 $102,735 $725 $222–$2,183 $149
2023 $75,973 $836 $257–$2,440 $160
2024 $36,638 $909 $252–$2,619 $164
2025 $13,723 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Silk Road Medical, Inc. $442,894 541 payments
  2. Boston Scientific Corporation $13,264 17 payments
  3. W. L. Gore & Associates, Inc. $2,400 35 payments
  4. Medtronic, Inc. $2,238 23 payments
  5. Medtronic Vascular, Inc. $792 10 payments
  6. Endologix, Inc. $637 8 payments
  7. Bard Peripheral Vascular, Inc. $629 11 payments
  8. Philips Electronics North America Corporation $283 5 payments
  9. Stryker Corporation $253 5 payments
  10. Penumbra, Inc. $247 4 payments
  11. Other $1,802 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $366,231 96 payments
  2. Travel and Lodging $61,132 278 payments
  3. Food and Beverage $22,937 314 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,875 4 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $4,250 1 payment
  6. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. ENROUTE Transcarotid Stent $297,185 382 payments
  2. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $297,185 382 payments
  3. ENROUTE 0.014 Guidewire $145,709 159 payments
  4. ENROUTE Transcarotid Stent System $145,709 159 payments
  5. ENROUTE Transcarotid Neuroprotection System Carotid Artery Disease $145,709 159 payments
  6. ENHANCE Transcarotid Peripheral Access Kit Carotid Artery Disease $145,709 159 payments
  7. ENHANCE Transcarotid Peripheral Access Kit Cardiology/Vascular Diseases $86,402 114 payments
  8. ENROUTE .014 Guidewire $86,402 114 payments
  9. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $34,127 49 payments
  10. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $34,127 49 payments
  11. Other $23,403 170 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. MicroVention, Inc. $14 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

127

Median for Vascular Surgery: 122

Drug cost

$1,038

Median for Vascular Surgery: $14,135

Branded share of claims

64.6%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 64 $716
Atorvastatin Calcium Generic 28 $156
Rosuvastatin Calcium Generic 17 $106
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 18 $59

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 112 billing codes

Paid by Medicare

$229,238

Medicare's payments for the services billed

Medicare patients

872

Average age 76

Services billed

1,550

444 women, 428 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 49%
Ischemic heart disease 46%
Chronic kidney disease 46%
Heart failure 37%
COPD 30%
Atrial fibrillation 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

695 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record